Vadodara-based Genexis Biotech has raised ₹4 crore in a seed funding round led by GVFL, with additional participation from Benzai10. The bio-manufacturing startup is focused on developing animal-origin-free recombinant proteins through precision fermentation and recombinant technology.
The funding will be used to expand bioreactor capacity, strengthen downstream processing infrastructure, and launch a suite of recombinant enzymes and smart proteins. Genexis will also invest in regulatory compliance, quality control, and building out its sales and distribution networks.
Founded in 2019 by Vipul Kumar and Jitendra Wagh, Genexis operates a Class 10,000 cleanroom facility and is in the process of establishing a GMP-compliant unit to support exports to regulated markets.
“We’re building India’s deeptech backbone for sustainable, animal-origin-free protein production,” said co-founder Vipul Kumar.
“Genexis is filling a crucial gap in India’s biotech value chain,” added Mihir Joshi, MD at GVFL. “Its R&D depth and infrastructure position it strongly for scale in biopharma, food-tech, and life sciences.”
Genexis has forged partnerships with pharma companies, biotech startups, and academic institutions, and signed an MoU with the Gujarat government in 2023 to expand recombinant protein manufacturing. The company also plans to develop encapsulated growth factors for cosmetic applications and engage with CDMOs.
The round underscores growing investor interest in India’s deeptech and biotech landscape, with GVFL continuing to back innovators across healthtech, cleantech, fintech, and enterprise software.
